ANTICARDIOLIPINIC ANTIBODIES IN NON-HODGKIN LYMPHOMA

Objective: Identification of hemostasis changes in patients with non-Hodgkin's lymphoma (NHL) and anticardiolipin antibodies (aCL). Methodology: The study included 83 patients (men-34, women-49) with a mean age of 63.2 years, with NHL, investigated complex, by research of lupus anticoagulant (L...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sanda Buruiana, Minodora Mazur, Maria Robu, Victor Tomacinschii
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/acdceef16bc1462c9fd4cf6fc4d45414
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:acdceef16bc1462c9fd4cf6fc4d45414
record_format	dspace
spelling	oai:doaj.org-article:acdceef16bc1462c9fd4cf6fc4d454142021-11-10T04:35:59ZANTICARDIOLIPINIC ANTIBODIES IN NON-HODGKIN LYMPHOMA2531-137910.1016/j.htct.2021.10.1036https://doaj.org/article/acdceef16bc1462c9fd4cf6fc4d454142021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921011834https://doaj.org/toc/2531-1379Objective: Identification of hemostasis changes in patients with non-Hodgkin's lymphoma (NHL) and anticardiolipin antibodies (aCL). Methodology: The study included 83 patients (men-34, women-49) with a mean age of 63.2 years, with NHL, investigated complex, by research of lupus anticoagulant (LA) by Turbidimetry; antiβ2glycoprotein I IgG, IgM and aCL antibodies, by ELISA method. Hemostasis disorders were evaluated according to the type of NHL, stage, tumor size. Results: aCL were detected in 10 (12%) patients: 6 patients with aggressive type lymphoma and 4 patients with indolent type lymphoma, with advanced stage B cell NHL in 60%, mean age 52.8 years. LA was present in 80% of cases, unlike aCL IgG antibodies (10%) and antiβ2glycoprotein I IgG (10%). Hemostasis disorders were found in 6 (60%) patients: thrombotic events-at 4 (40%) patients with Mantle cell lymphoma (1 patient), Small lymphocytic lymphoma (1 patient), lymphoblastic lymphoma (2 patients). Local stage (I and II) of the lymphoma was in 75%, but with a large size of the tumor (> 11 cm), and hemorrhage at 2 (20%) patients with stage IV Small lymphocytic lymphoma, in which immune thrombocytopenia developed. Conclusion: The presence of antiphospholipid antibodies, in particular of lupus anticoagulant, advanced age, generalized stage, and large tumor size are risk factors for the development of hemostasis diseases in NHL patients, especially thrombosis.Sanda BuruianaMinodora MazurMaria RobuVictor TomacinschiiElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S42- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Sanda Buruiana Minodora Mazur Maria Robu Victor Tomacinschii ANTICARDIOLIPINIC ANTIBODIES IN NON-HODGKIN LYMPHOMA
description	Objective: Identification of hemostasis changes in patients with non-Hodgkin's lymphoma (NHL) and anticardiolipin antibodies (aCL). Methodology: The study included 83 patients (men-34, women-49) with a mean age of 63.2 years, with NHL, investigated complex, by research of lupus anticoagulant (LA) by Turbidimetry; antiβ2glycoprotein I IgG, IgM and aCL antibodies, by ELISA method. Hemostasis disorders were evaluated according to the type of NHL, stage, tumor size. Results: aCL were detected in 10 (12%) patients: 6 patients with aggressive type lymphoma and 4 patients with indolent type lymphoma, with advanced stage B cell NHL in 60%, mean age 52.8 years. LA was present in 80% of cases, unlike aCL IgG antibodies (10%) and antiβ2glycoprotein I IgG (10%). Hemostasis disorders were found in 6 (60%) patients: thrombotic events-at 4 (40%) patients with Mantle cell lymphoma (1 patient), Small lymphocytic lymphoma (1 patient), lymphoblastic lymphoma (2 patients). Local stage (I and II) of the lymphoma was in 75%, but with a large size of the tumor (> 11 cm), and hemorrhage at 2 (20%) patients with stage IV Small lymphocytic lymphoma, in which immune thrombocytopenia developed. Conclusion: The presence of antiphospholipid antibodies, in particular of lupus anticoagulant, advanced age, generalized stage, and large tumor size are risk factors for the development of hemostasis diseases in NHL patients, especially thrombosis.
format	article
author	Sanda Buruiana Minodora Mazur Maria Robu Victor Tomacinschii
author_facet	Sanda Buruiana Minodora Mazur Maria Robu Victor Tomacinschii
author_sort	Sanda Buruiana
title	ANTICARDIOLIPINIC ANTIBODIES IN NON-HODGKIN LYMPHOMA
title_short	ANTICARDIOLIPINIC ANTIBODIES IN NON-HODGKIN LYMPHOMA
title_full	ANTICARDIOLIPINIC ANTIBODIES IN NON-HODGKIN LYMPHOMA
title_fullStr	ANTICARDIOLIPINIC ANTIBODIES IN NON-HODGKIN LYMPHOMA
title_full_unstemmed	ANTICARDIOLIPINIC ANTIBODIES IN NON-HODGKIN LYMPHOMA
title_sort	anticardiolipinic antibodies in non-hodgkin lymphoma
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/acdceef16bc1462c9fd4cf6fc4d45414
work_keys_str_mv	AT sandaburuiana anticardiolipinicantibodiesinnonhodgkinlymphoma AT minodoramazur anticardiolipinicantibodiesinnonhodgkinlymphoma AT mariarobu anticardiolipinicantibodiesinnonhodgkinlymphoma AT victortomacinschii anticardiolipinicantibodiesinnonhodgkinlymphoma
_version_	1718440586681253888

ANTICARDIOLIPINIC ANTIBODIES IN NON-HODGKIN LYMPHOMA

Ejemplares similares